

The therapeutic potential of microdosing psychedelics in depression	
Title of Periodical	Therapeutic Advances in Psychopharmacology
Volume/Issue Number	Volume 10
Publication Date	27/08/2020
Author	Kim P.C. Kuypers
Most relevant passages or drawings	Page 2
Relevant to claims	Claims 1, 3, 16, 19
Brief explanation of relevance	From page 2 “In general, a microdose is considered to be one tenth of a dose normally causing hallucinogenic effects. When taking the doses used in clinical research as a reference, <sup>2,4</sup> a microdose then would be 10–20mcg of LSD and/or 0.3–0.5g of psilocybin-containing mushrooms. <sup>15,16</sup> In a recent survey, users reported taking between 6 and 20mcg LSD and 0.2–0.5g of dried psilocybin mushrooms <sup>13,17,18</sup> with a microdosing frequency that ranges between 2 and 4times a week, this for a few weeks, to months, or even years, although the latter is rare. <sup>15,18</sup> Reported short-term benefits of microdosing include an increase in positive mood, a decrease in negative mood, and in improvement relationships with others and their environment, <sup>15,17–21</sup> which seems to be in line with the effects of full psychedelic doses, though without the perceptual effects.” Relevant to WO2022235529 claims 1, 3, 16, 1

Methods, Devices, and Systems for Pulmonary Delivery of Active Agents	
Country Code	US
Publication Number	20170157343
Document Kind	B2
Publication Date	08/06/2017
Filing Date	11/12/2016
Priority Date	21/05/2015
Patent Applicant/Patent Owner	Syqe Medical Ltd.
Most relevant passages or drawings	Paragraphs 0261, 0502; Claim 12
Relevant to claims	1 2, 4, 5, 6, 7, 16, 17, 18, 20, 21, 22, 24
Brief explanation of relevance	From paragraph [0502] “ In some embodiments, individual pre-selected vaporized amounts (doses) ..., are released electronically ... in amount increments of 0.1 mg, ranging from 0.1 to 6.0 mg, 0.3 to 1.7 mg, 0.1 to 2.0 mg, from 0.2 to 1.9 mg, from 0.2 to 1.8 mg, from 0.3 to 1.8 mg, from 0.3 to 1.6 mg, from 0.4 to 1.6 mg, from 0.5 to 2.0 mg, from 0.6 to 2.0 mg or from 0.3 to 0.9 mg, including any subranges and

	<p>any intermediate values therebetween.” Relevant to WO2022235529 claims 1, 2, 4, 6, 7, 17, 18, 20, 22, 24</p> <p>From paragraph [0261] “ The window may relate to a given point in time or may span a period of time of any length, including for example minutes, hours, days or longer, shorter or to any intermediate period of time.” Relevant to WO2022235529 claims 5, 16, 21,</p> <p>From Claim 12 “A method for treating or improving neurological or mental health condition comprising an amount of said formulation of <u>claim 1</u> applied to a subject thereof, wherein said neurological or mental health condition comprises: anxiety, post-traumatic stress disorder, attention deficit disorders, depression, memory loss, dementia, cognitive dysfunction, hearing loss, vision loss, neurologic pain, insomnia, erectile dysfunction, physiological pain or discomfort, or combinations thereof.” Relevant to WO2022235529 claim 17</p>
--	--

Metered Dosing Compositions and Methods of Use of Psychedelic Compounds	
Country Code	US
Publication Number	20220304980
Document Kind	A1
Publication Date	29/09/2022
Filing Date	03/07/2022
Priority Date	04/07/2020
Patent Applicant/Patent Owner	SW Holdings, Inc
Most relevant passages or drawings	Paragraph 0027
Relevant to claims	8, 10, 24
Brief explanation of relevance	From [0027] “Disclosed herein are new compositions and methods comprising a metered-dose(s) of the following “psychedelic compounds” or substances: Psilocybin... mescaline... N,N-dimethyltryptamine, N,N-DMT, 5-MeO-DMT... “ Relevant to WO2022235529 claims 8, 10, 24

What are Medication Blister Packs?	
URL	<a href="https://drugpackage.com/whats-new/what-are-blister-packs/">https://drugpackage.com/whats-new/what-are-blister-packs/</a>
Publication Date	11/05/2016
Retrieval Date	01/07/2023
Most relevant passages or drawings	Quotes from web page
Relevant to claims	14, 15

Brief explanation of relevance	<p>“A Medication Blister Pack is a card that packages doses of medication within small, clear, or light-resistant amber-colored plastic bubbles (or blisters). Each pack is secured by a strong, paper-backed foil that protects the pills until dispensed. When it’s time to take a dose of medication, the caregiver or patient simply pushes a blister of pills through the foil backing to distribute an accurate dose effortlessly.” Relevant to WO2022235529 claim 15</p> <p>“Medication Blister Packs can be organized both by day and time of day, such as morning/noon/evening/bedtime. Drug Package offers a range of single-dose and multi-dose options, including our popular 28-count size, ideal for Long-Term Care use, and our 31-count with extra-large blisters to hold a wider variety of pill sizes.” Relevant to WO2022235529 claims 11, 13, 14</p>
--------------------------------	--